2017
DOI: 10.1146/annurev-pharmtox-091616-023708
|View full text |Cite
|
Sign up to set email alerts
|

Introduction to the Theme “New Methods and Novel Therapeutic Approaches in Pharmacology and Toxicology”

Abstract: Major advances in scientific discovery and insights can result from the development and use of new techniques, as exemplified by the work of Solomon Snyder, who writes a prefatory article in this volume. The Editors have chosen "New Methods and Novel Therapeutic Approaches in Pharmacology and Toxicology" as the Theme for a number of articles in this volume. These include ones that review the development and use of new experimental tools and approaches (e.g., nanobodies and techniques to explore protein-protein… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
3
3

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(3 citation statements)
references
References 15 publications
(4 reference statements)
0
3
0
Order By: Relevance
“…The most important components are B1 (PB1), which contains aliphatic (S)‐6‐methyl‐octyl, and polymyxin B2 (PB2), which contains aliphatic 6‐methyl‐heptyl 3 . At present, PB1 and PB2 are mainly used in pharmacokinetic (PK) determination, accounting for approximately 85% of PB use 4 . Compared with polymyxin E, PB has an excellent PK effect and lower renal toxicity and is more frequently administered in the clinical practice.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…The most important components are B1 (PB1), which contains aliphatic (S)‐6‐methyl‐octyl, and polymyxin B2 (PB2), which contains aliphatic 6‐methyl‐heptyl 3 . At present, PB1 and PB2 are mainly used in pharmacokinetic (PK) determination, accounting for approximately 85% of PB use 4 . Compared with polymyxin E, PB has an excellent PK effect and lower renal toxicity and is more frequently administered in the clinical practice.…”
Section: Introductionmentioning
confidence: 99%
“…3 At present, PB1 and PB2 are mainly used in pharmacokinetic (PK) determination, accounting for approximately 85% of PB use. 4 Compared with polymyxin E, PB has an excellent PK effect and lower renal toxicity and is more frequently administered in the clinical practice. According to the drug instructions, the commonly used dose of PB is 1.5-2.5 mg/kg per day, divided evenly into two doses.…”
Section: Introductionmentioning
confidence: 99%
“…Moreover, a large number of chemical substances need to be studied to identify the adverse effects on development, metabolic homeostasis, reproduction, cytotoxicity, etc. (Zhu et al, 2014; Bell et al, 2017; Insel et al, 2017; Juberg et al, 2017; Clark and Steger-Hartmann, 2018; Mortensen et al, 2018). Thus, high-throughput (HTP) assays and economical methods are required (Tollefsen et al, 2014; Chen et al, 2015; Wang et al, 2015; Richard et al, 2016).…”
Section: Introductionmentioning
confidence: 99%